Last reviewed · How we verify

PTH followed by dose dense AC of FEC

Agendia · FDA-approved active Small molecule

This is a chemotherapy regimen combining paclitaxel/trastuzumab (PTH) followed by dose-dense doxorubicin/cyclophosphamide (AC) or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) to treat HER2-positive breast cancer.

This is a chemotherapy regimen combining paclitaxel/trastuzumab (PTH) followed by dose-dense doxorubicin/cyclophosphamide (AC) or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) to treat HER2-positive breast cancer. Used for HER2-positive early-stage breast cancer (neoadjuvant or adjuvant setting).

At a glance

Generic namePTH followed by dose dense AC of FEC
SponsorAgendia
Drug classCombination chemotherapy regimen with monoclonal antibody
TargetHER2 receptor; microtubule; DNA (topoisomerase II)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

PTH targets HER2-positive cancer cells through trastuzumab (anti-HER2 monoclonal antibody) combined with paclitaxel (microtubule stabilizer). This is followed by dose-dense anthracycline-based chemotherapy (AC or FEC regimens) which intercalates DNA and generates reactive oxygen species to kill rapidly dividing cells. The sequential combination leverages different mechanisms of action to maximize efficacy in HER2-positive breast cancer.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: